Author(s):
Damayanti, Cita Rosita Sigit Prakoeswa, Sylvia Anggraeni, Menul Ayu Umborowati, Maylita Sari, Made Putri Hendaria
Email(s):
cita-rosita@fk.unair.ac.id
DOI:
10.52711/0974-360X.2024.00793 
Address:
Damayanti1,2, Cita Rosita Sigit Prakoeswa3,4*, Sylvia Anggraeni1,2, Menul Ayu Umborowati1,2, Maylita Sari1,2, Made Putri Hendaria1,2
1Researcher, Department of Dermatology Venereology and Aesthetic, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
2Researcher, Department of Dermatology Venereology and Aesthetic, Faculty of Medicine Universitas Airlangga, Surabaya, Indonesia.
3Professor, Department of Dermatology Venereology and Aesthetic, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
4Professor, Department of Dermatology Venereology and Aesthetic, Faculty of Medicine Universitas Airlangga, Surabaya, Indonesia.
*Corresponding Author
Published In:
Volume - 17,
Issue - 11,
Year - 2024
ABSTRACT:
Atopic dermatitis (AD) is a chronic, inflammatory skin condition and has a variable natural course. AD can affect a person in their childhood before they seem to "grow out of it" but later in life they could develop sensitive skin. Therapy of AD is aimed at preventing recurrence, repairing damaged skin barrier, maintaining hydration of the stratum corneum, and overcoming inflammation. Topical steroids used in AD are feared to cause local and systemic side effects. Recent management of AD mainly emphasizes the use of moisturizers especially moisturizer that has anti-inflammatory agents. This study was aimed to analyze the role of moisturizer containing antiinflammatory agent in the clinical improvement of AD patients. This study was a double-blind randomized clinical trial. The inclusion criteria were patients aged 18-64 years with mild-moderate AD who met the criteria for the diagnosis according to the Hanifin-Rajka criteria, in good general condition and willing to participate in the study. Subjects were randomly divided into two groups, 16 people in the control group receiving moisturizer without antiinflammatory agents and 16 people in the intervention group receiving moisturizer with antiinflammatory agents. The clinical improvement were evaluated after 14 days of treatment, using Scoring Atopic Dermatitis (SCORAD) evaluation. There was a significant difference in SCORAD (p<0.05) in the baseline and day 14 in the intervention group (21.51 ± 3.42 to 16.25 ± 3.35) and the control group (19.96 ± 2.08 to 17.02 ± 2.04). There was also a significant difference in the clinical improvement in SCORAD outcome between both groups. The addition of antiinflammatory ingredients to moisturizer has been shown to make a significant difference in improving SCORAD outcome in mild to moderate AD patients.
Cite this article:
Damayanti, Cita Rosita Sigit Prakoeswa, Sylvia Anggraeni, Menul Ayu Umborowati, Maylita Sari, Made Putri Hendaria. The Role of Moisturizer Containing Antiinflamatory Agent in Clinical Improvement of Atopic Dermatitis: A Double-Blind Randomized Clinical Trial. Research Journal of Pharmacy and Technology. 2024; 17(11):5183-8. doi: 10.52711/0974-360X.2024.00793
Cite(Electronic):
Damayanti, Cita Rosita Sigit Prakoeswa, Sylvia Anggraeni, Menul Ayu Umborowati, Maylita Sari, Made Putri Hendaria. The Role of Moisturizer Containing Antiinflamatory Agent in Clinical Improvement of Atopic Dermatitis: A Double-Blind Randomized Clinical Trial. Research Journal of Pharmacy and Technology. 2024; 17(11):5183-8. doi: 10.52711/0974-360X.2024.00793 Available on: https://rjptonline.org/AbstractView.aspx?PID=2024-17-11-1
REFERENCES:
1. Cork M. Robinson DA. Article in Community practitioner: the journal of the Community Practitioners’ and Health Visitors’ Association. [Internet]. 2006; Available from: https://www.researchgate.net/publication/7396312
2. Simpson EL. Leung DYM.Eichenfield LF.Boguniewicz M. Atopic Dermatitis. In: Kang S. Amagai M. Bruckner AL. Enk AH. Margolis DJ. McMichael AJ. et al., editors. Fitzpatrick’s Dermatology. 9th ed. New York: McGraw-Hill Education 2019; 363–84.
3. Al-Adawiyah R. Putera AM.Astari L.Ariyanto FC. Determinant factors of recurrence atopic dermatitis symptoms in children: A cross-sectional study. Annals of Medicine and Surgery. 2021; Oct 1;70. doi: 10.1016/j.amsu.2021.102847
4. Herwanto N.Hutomo M. Studi Retrospektif: Penatalaksanaan Dermatitis Atopik (Retrospective Study: Management of Atopic Dermatitis). BerkalaIlmu Kesehatan Kulit dan Kelamin. 2016; 28(1): 45–54.
5. Han M. Wang X. Wang J. Lang D. Xia X. Jia Y. et al. Ameliorative effects of epigallocatechin-3-gallate nanoparticles on 2,4-dinitrochlorobenzene induced atopic dermatitis: A potential mechanism of inflammation-related necroptosis. Front Nutr. 2022; Aug 9; 9. doi: 10.3389/fnut.2022.953646
6. Sirikudta W. Moisturizers for Patients with Atopic Dermatitis: An Overview. J Allergy Ther [Internet]. 2013;04(04). Available from: https://www.omicsonline.org/moisturizers-for-patients-with-atopic-dermatitis-an-overview-2155-6121.1000143.php?aid=15728
7. Panther D. Jacob S. The Importance of Acidification in Atopic Eczema: An Underexplored Avenue for Treatment. J Clin Med. 2015; May 18; 4(5): 970–8. doi: 10.3390/jcm4050970
8. van Zuuren EJ. Fedorowicz Z. Arents BWM. Performance and Tolerability of the Moisturizers Cetaphil® and Excipial® in Atopic Dermatitis: What is the Evidence Based on Randomized Trials? Dermatol Ther (Heidelb). 2017; Sep. 9; 7(3): 331–47. doi: 10.1007/s13555-017-0184-3
9. Catherine Mack Correa M. Nebus J. Management of Patients with Atopic Dermatitis: The Role of Emollient Therapy. Dermatol Res Pract. 2012; 1–15. doi: 10.1155/2012/836931
10. Hon KL. Kung JSC. Ng WGG. Leung TF. Emollient treatment of atopic dermatitis: latest evidence and clinical considerations. Drugs Context. 2018; Apr 17; 7: 1–14. doi: 10.7573/dic.212530
11. Siswati AS.Prakoeswa CRS.Triwahyudi D.Budianti WK.Mawardi P.Dwiyana RF. et al. Panduan PraktikKlinis Bagi Dokter SpesialisDermatologi Dan Venereologi Indonesia. Jakarta; 2021.
12. Feldman SR. Cox LS. Strowd LC. Gerber RA. Faulkner S.Sierka D. Smith TW.Cappelleri JC. Levenberg ME. The Challenge of Managing Atopic Dermatitis in the United States. Am Health Drug Benefits. 2019; Apr; 12(2): 83-93. PMID: 31057694; PMCID: PMC6485648.
13. Rubel D. Thirumoorthy T.Soebaryo RW. Weng SCK. Gabriel TM. Villafuerte LL. et al. Consensus guidelines for the management of atopic dermatitis: An Asia-Pacific perspective. Journal of Dermatology. 2013; Mar; 40(3): 160–71. doi: 10.1111/1346-8138.12065
14. Giam YC. Hebert AA. Dizon MV. Van Bever H. Tiongco-Recto M. Kim KH.Soebono H. Munasir Z. Diana IA. Luk DC. A review on the role of moisturizers for atopic dermatitis. Asia Pac Allergy. 2016; Apr; 6(2): 120-8. doi: 10.5415/apallergy.2016.6.2.120. Epub 2016 Apr 28. PMID: 27141486; PMCID: PMC4850335.
15. Coondoo A.Phiske M. Verma S. Lahiri K. Side-effects of topical steroids: A long overdue revisit. Indian Dermatol Online J. 2014; Oct; 5(4): 416-25. doi: 10.4103/2229-5178.142483. PMID: 25396122; PMCID: PMC4228634.
16. Varothai S.Nitayavardhana S.Kulthanan K. Moisturizers for patients with atopic dermatitis. Asian Pac J Allergy Immunol. 2013; Jun; 31(2): 91-8. PMID: 23859407.
17. Angelova-Fischer I.Neufang G. Jung K. Fischer TW.Zillikens D. A randomized, investigator-blinded efficacy assessment study of stand-alone emollient use in mild to moderately severe atopic dermatitis flares. J EurAcad Dermatol Venereol. 2014; May; 28 Suppl 3: 9-15. doi: 10.1111/jdv.12479. PMID: 24702445.
18. Gueniche A.Knaudt B. Schuck E. Volz T. Bastien P. Martin R.Röcken M. Breton L. Biedermann T. Effects of nonpathogenic gram-negative bacterium Vitreoscillafiliformis lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study. Br J Dermatol. 2008; Dec; 159(6): 1357-63. doi: 10.1111/j.1365-2133.2008.08836.x.Epub 2008 Sep 15. PMID: 18795916.
19. Diana IA. Boediardja SA. Sugito TL. Lokanata MD. Prihianti S. Danarti R. et al. Panduan Diagnosis Dan Tatalaksana Dermatitis Atopik Di Indonesia. 1st ed. Jakarta: KSDAI; 2014.
20. Hidayati AN.Sawitri S. Sari DW.Prakoeswa CRS.Indramaya DM. Damayanti D. Zulkarnain I.Citrashanty I. Widia Y.Anggraeni S. Efficacy of vitamin D supplementation on the severity of atopic dermatitis in children: A systematic review and meta-analysis. F1000Res. 2023; Sep 25; 11: 274. doi: 10.12688/f1000research.106957.2. PMID: 37829249; PMCID: PMC10565422.
21. Boguniewicz M. Fonacier L. Guttman-Yassky E. Ong PY. Silverberg J. Farrar JR. Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018; Jan; 120(1): 10-22.e2. doi: 10.1016/j.anai.2017.10.039. PMID: 29273118.
22. Marinho A. Nunes C. Reis S. Hyaluronic acid: A key ingredient in the therapy of inflammation. Vol. 11, Biomolecules. MDPI; 2021.
23. How KN. Yap WH. Lim CLH. Goh BH. Lai ZW. Hyaluronic Acid-Mediated Drug Delivery System Targeting for Inflammatory Skin Diseases: A Mini Review. Front Pharmacol. 2020; Jul 24; 11: 1105. doi: 10.3389/fphar.2020.01105. PMID: 32848737; PMCID: PMC7397973.
24. Andersson AC. Alander AAK J. Shea butter extract for bioactive skin care. Cosmetics and Toiletries Research. 2015; 130: 18–25.
25. Sánchez-Quesada C. López-Biedma A. Toledo E.Gaforio JJ. Squalene Stimulates a Key Innate Immune Cell to Foster Wound Healing and Tissue Repair. Evid Based Complement Alternat Med. 2018; Sep 30; 2018: 9473094. doi: 10.1155/2018/9473094. PMID: 30363968; PMCID: PMC6186384.
26. Sethi A. Kaur T. Malhotra SK. Gambhir ML. Moisturizers: The Slippery Road. Indian J Dermatol. 2016; May-Jun; 61(3): 279-87. doi: 10.4103/0019-5154.182427. PMID: 27293248; PMCID: PMC4885180.
27. Gueniche A.Liboutet M.Cheilian S. Fagot D.Juchaux F. Breton L. Vitreoscillafiliformis Extract for Topical Skin Care: A Review. Front Cell Infect Microbiol. 2021; Dec 16; 11: 747663. doi: 10.3389/fcimb.2021.747663. PMID: 34976852; PMCID: PMC8717924.
28. Gueniche A. Valois A. Kerob D.Rasmont V. Nielsen M. A combination of Vitreoscillafiliformis extract and Vichy volcanic mineralizing water strengthens the skin defenses and skin barrier. J EurAcad Dermatol Venereol. 2022; Jan; 36 Suppl 2: 16-25. doi: 10.1111/jdv.17786. PMID: 34979591.
29. Volz T.Skabytska Y.Guenova E. Chen KM. Frick JS.Kirschning CJ.Kaesler S.Röcken M. Biedermann T. Nonpathogenic bacteria alleviating atopic dermatitis inflammation induce IL-10-producing dendritic cells and regulatory Tr1 cells. J Invest Dermatol. 2014; Jan; 134(1): 96-104. doi: 10.1038/jid.2013.291. Epub 2013 Jun 28. PMID: 23812300.
30. Paller A. Nardi R. Do H. Reha A. Viereck C. Castelli J. An investigation into multifaceted mechanisms of action of allantoin in wound healing. J Am Acad Dermatol. 2017; Jun; 76(6): AB40.
31. Vanessa VV. Wan Ahmad Kammal WSL. Lai ZW. How KN. A Review of Moisturizing Additives for Atopic Dermatitis. Vol. 9, Cosmetics. MDPI; 2022. https://doi.org/10.3390/cosmetics9040075
32. Eddin LB. Jha NK. Goyal SN. Agrawal YO. Subramanya SB.Bastaki SMA. Ojha S. Health Benefits, Pharmacological Effects, Molecular Mechanisms, and Therapeutic Potential of α-Bisabolol. Nutrients. 2022; Mar 25; 14(7): 1370. doi: 10.3390/nu14071370. PMID: 35405982; PMCID: PMC9002489.
33. John S. Active Agent Complex and Formulation Compromising The Active Agent Complex [Internet]. United States: United States Patent; US9549957B2, 2017; p. 1–8. Available from: www.personalcaremagazine.com/Story.aspx?Story=6377
34. Bae MJ. See HJ. Choi G. Kang CY. Shon DH. Shin HS. Regulatory T Cell Induced by Poria cocos Bark Exert Therapeutic Effects in Murine Models of Atopic Dermatitis and Food Allergy. Mediators Inflamm. 2016;2016:3472608. doi: 10.1155/2016/3472608. Epub 2016; Jun 29. PMID: 27445434; PMCID: PMC4942653.
35. Chao CL. Wang CJ. Huang HW. Kuo HP. Su MH. Lin HC. Teng CW. Sy LB. Wu WM. Poria cocos Modulates Th1/Th2 Response and Attenuates Airway Inflammation in an Ovalbumin-Sensitized Mouse Allergic Asthma Model. Life (Basel). 2021; Apr 21; 11(5): 372. doi: 10.3390/life11050372. PMID: 33919400; PMCID: PMC8143325.
36. Choi E. Kang YG. Hwang SH. Kim JK. Hong YD. Park WS. Kim D. Kim E. Cho JY. In vitro Effects of Dehydrotrametenolic Acid on Skin Barrier Function. Molecules. 2019; Dec 14; 24(24): 4583. doi: 10.3390/molecules24244583. PMID: 31847353; PMCID: PMC6943483.
37. Maxia A. Sanna C. Salve B. Kasture A. Kasture S. Inhibition of histamine mediated responses by Mirabilis jalapa: confirming traditional claims made about antiallergic and antiasthmatic activity. Nat Prod Res. 2010; Nov; 24(18): 1681-6. doi: 10.1080/14786410802632804. PMID: 20981612.
38. Nath LR. Manjunath KP.Savadi RV. Akki KS. Anti-Inflammatory Activity of Mirabilis Jalapa Linn. Leaves. J Basic Clin Pharm [Internet]. 2010; 1(2): 93–6. Available from: www.jbclinpharm.com
39. Kang SY. Um JY. Chung BY. Lee SY. Park JS. Kim JC. Park CW. Kim HO. Moisturizer in Patients with Inflammatory Skin Diseases. Medicina (Kaunas). 2022; Jul 1; 58(7): 888. doi: 10.3390/medicina58070888. PMID: 35888607; PMCID: PMC9315586.
40. Ueda Y. Murakami Y. Saya Y. Matsunaka H. Optimal application method of a moisturizer on the basis of skin physiological functions. J Cosmet Dermatol. 2022; Jul; 21(7): 3095-3101. doi: 10.1111/jocd.14560. Epub 2021 Nov 7. PMID: 34743412; PMCID: PMC9543289.